




A novel methylated analogue of *L*-Mimosine exerts its therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma

Sotiris Kyriakou^{1,2,3} · William Cheung¹ · Theodora Mantso¹ · Melina Mitsiogianni¹ · Ioannis Anastopoulos^{2,3} · Stephany Veuger¹ · Dimitris T. Trafalis⁴ · Rodrigo Franco^{5,6} · Aglaia Pappa⁷ · David Tetard¹ · Mihalis I. Panayiotidis^{1,2,3} 

Received: 12 January 2021 / Accepted: 11 February 2021 / Published online: 23 February 2021
© The Author(s) 2021

Summary

Melanoma is an aggressive and highly metastatic type of skin cancer where the design of new therapies is of utmost importance for the clinical management of the disease. Thus, we have aimed to investigate the mode of action by which a novel methylated analogue of *L*-Mimosine (e.g., *L*-SK-4) exerts its therapeutic potency in an in vitro model of malignant melanoma. Cytotoxicity was assessed by the Alamar Blue assay, oxidative stress by commercially available kits, ROS generation, caspase 3/7 activation and mitochondrial membrane depolarisation by flow cytometry, expression of apoptosis-related proteins by western immunoblotting and profiling of lipid biosynthesis by a metabolomic approach. Overall, higher levels of ROS, sphingolipids and apoptosis were induced by *L*-SK-4 suggesting that the compound's therapeutic potency is mediated through elevated ROS levels which promote the upregulation of sphingolipid (ceramide) biosynthesis thus leading to the activation of both extrinsic and intrinsic apoptosis, in an experimental model of malignant melanoma.

Keywords Metal chelators · Melanoma · Oxidative stress · Glutathione · Ceramide · Apoptosis

Introduction

Reactive oxygen species (ROS) are generated as by-products of oxygen consumption in mitochondria and/or from other

exogenous sources such as pollutants, tobacco, xenobiotics, radiation, etc. [1, 2].

The beneficial role of ROS has been demonstrated multiple times in the literature like in the case of immune response induction [3]. More specifically, activation of surveillance receptors leads to elevation of ROS that is essential for the release of pro-inflammatory cytokines [interleukin 1 β (IL-1 β), tumor necrosis factor α (TNF α) and interferon β (IFN- β)] which are required for the activation and regulation of an appropriate immune response. Consequently, low levels of ROS can lead to immunosuppression by preventing activation of an immune response [4–6]. Moreover, ROS can influence cell proliferation through regulation of cell cycle progression by acting as second messengers capable of mediating the phosphorylation and ubiquitination of CDKs via activation of the EGF-receptor [7–9].

On the other hand, increased levels of ROS can cause undesirable effects. For instance, they contribute to carcinogenesis through lipid peroxidation, protein carbonylation and DNA/RNA oxidative damage all of which can lead to genetic instability and tumorigenesis [9–13]. However, excessive

✉ Mihalis I. Panayiotidis
mihalis@cing.ac.cy

¹ Department of Applied Sciences, Northumbria University, Newcastle Upon Tyne, UK

² Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus

³ The Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus

⁴ Department of Pharmacology, Medical School, National & Kapodistrian University of Athens, Athens, Greece

⁵ Redox Biology Centre, University of Nebraska, Lincoln, USA

⁶ School of Veterinary Medicine & Biomedical Sciences, University of Nebraska, Lincoln, USA

⁷ Department of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece

accumulation of ROS, in cancer cells, can lead to anti-tumorigenic effects by means of rendering them vulnerable to the activation of apoptotic cell death. Thus, cancer therapeutic strategies are designed with the scope to induce ROS generation and consequently trigger an apoptotic response [14, 15]. To this end, it has been previously demonstrated that many chemotherapeutic drugs have the capacity to inhibit the intracellular antioxidant response and thus cause accumulation of ROS which allows for drug-induced cytotoxicity [15]. Nevertheless, the main disadvantage of such approach(es) is the lack of specificity as chemotherapeutic agents cannot target selectively cancer cells [13].

The anti-cancer activity of hydroxypyridone-based (HOPO) metal chelators has been documented, in the past, by others [16, 17] as well as by our research group [18]. More specifically, we have previously shown that treatment of malignant melanoma (A375) cells with a novel *N*-substituted 3,4-HOPO compound (*L*-SK-4) can induce the activation of both intrinsic and extrinsic apoptotic cascades as well as perturbations in cell cycle and ROS homeostasis [18]. Interestingly, an immortalized, non-tumorigenic keratinocyte cell line was shown to be more resistant to the action of *L*-SK-4; thus, proving the compound's specificity against its potential target. Consequently, we have employed an in vitro model of malignant melanoma consisting of non-metastatic (A375 and B16F-10) as well as metastatic (VMM1 and Hs294T) melanoma cell lines in addition to non-melanoma epidermoid carcinoma (A431) and non-malignant immortalized melanocyte neighbouring keratinocyte (HaCaT) cells. The aim of this study was to investigate the mode of action by which *L*-SK-4 activates the apoptotic response in order to delineate the underlying mechanisms by which it exerts its previously described therapeutic potency [18].

Materials and methods

Chemicals

SK-1, SK-2, SK-3, *D*-SK-4, *L*-SK-4 and SK-5 were previously synthesized, purified and characterized [18]. GSH, resazurin sodium salt and Myriocin were purchased from Sigma-Aldrich (St. Louis, MO, USA). All media and cell culture material were obtained from LabTech International Ltd. (East Sussex, UK). Bovine Serum Albumin (BSA) was obtained from Biosera (Boussens, France). Protease and phosphatase inhibitor cocktails were obtained from Roche (Basel, Switzerland). Polyvinylidene difluoride (PVDF) membranes (0.45 and 0.2 μ m) were purchased from Millipore (Bedford, MA, USA). All solvents were of UHPLC optima grade or better.

Cell lines

A375 and A431 cells were purchased from Sigma-Aldrich (St. Louis, MO, USA). In addition, VMM1, Hs294T and B16F10 cells were obtained from LGC Standards (Middlesex, UK). All cell lines were maintained in a humidified atmosphere at 37 °C, 5% CO₂ and according to the provider's recommended culture conditions. All media and reagents were purchased from Labtech (East Sussex, UK). All plasticware were obtained from Corning (Corning, NY, USA).

Determination of cell viability

Briefly, A375 cells were seeded in 100 μ L/well into 96-well plates and incubated overnight. On the following day, cells were exposed to either GSH (1.5–3.0 mM) or Myriocin (0–50 μ M) with or without *L*-SK-4 (100 μ M) over different incubation periods while control cells were incubated with complete medium only. The Alamar-blue assay was utilized as previously described [18].

Determination of ROS

Cells were seeded in 60 mm dishes and then exposed to *L*-SK-4 (100 μ M) with or without pre-treatment with either GSH (1.5 mM) or Myriocin (50 nM). Then, they were harvested and washed twice with PBS after which, a single cell suspension of 10⁶ cells/mL was prepared. Dihydrorhodamine 123 (DHR 123; 10 μ M) was added in the suspension and incubated for 5 mins at 37 °C followed by addition of DAPI (1 μ M), in each sample, and further incubation for 5 mins. Data acquisition and analysis of 10,000 events, for each sample, was performed using a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA). DAPI-positive cells were excluded from further analyses.

Determination of apoptosis

The CellEvent Caspase 3/7 Green flow cytometry assay kit was utilized for the detection of apoptosis according to the manufacturer's instructions. Briefly, cells were seeded and allowed to adhere overnight in 60 mm dishes and then exposed to *L*-SK-4 (100 μ M) with or without pre-treatment with either GSH (1.5 mM) or Myriocin (50 nM). Next, cells were harvested and washed twice with PBS after which, a single cell suspension of 10⁶ cells/mL was prepared. Then, 0.5 μ L of CellEvent Caspase 3/7 Green detection reagent was added into 0.5 mL of each cell suspension and samples were incubated at 37 °C for 30 mins followed by addition of DAPI (1 μ M), in each sample, and further incubation for 5 mins. Data acquisition and analysis of 20,000 events, for each sample, was performed using a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA).

Determination of mitochondria membrane depolarization

The JC-1 staining solution was used according to the manufacturer's instructions. Following treatment with *L*-SK-4 (100 μ M) with or without pre-treatment with myriocin (50 nM), cells were harvested and washed twice in PBS. Then, 0.3 μ L of JC-1 (0.1 mg/mL) was added into 0.3 mL of each cell suspension, in PBS, and samples were incubated at 37 °C for 30 mins. All cell suspensions were centrifuged at 1000 rpm for 5 mins and pellets were re-suspended in fresh PBS. Data acquisition and analysis of 10,000 events, for each sample, was performed using a FACS Canto II flow cytometer (BD Biosciences, San Jose, CA, USA).

Preparation of cell lysates and protein determination

A375 cells were plated in 100 mm dishes and cultured overnight at 37 °C. Next day, cells were treated with *L*-SK-4 (100 μ M) with or without pre-treatment with either GSH (1.5 mM) or myriocin (50 nM) for 24, 48 and 72 h. Cell lysates were prepared and obtained as previously described [18]. Protein content was determined by utilizing the BCA protein assay kit (Thermo Scientific, Waltham, MA, USA), according to the manufacturer's protocols. Protein extracts were stored at -20 °C until usage.

Western immunoblotting

Standard conditions were used as previously described [18]. All antibodies (e.g., anti-Caspases-8 and -9, anti-Apaf-1, anti-BID, anti-FADD, anti-FAS, anti-BAX, anti-BAK and anti-Tubulin) were purchased from Cell Signaling Technology (Danvers, MA, USA) and utilized according to the manufacturer's protocol.

Determination of lipid peroxidation content

A375 cells were plated in 100 mm dishes, cultured overnight and next day were treated with *L*-SK-4 (100 μ M). After trypsinization, pellets were collected, re-suspended and sonicated before the TBARS Assay kit (Cambridge Bioscience Ltd., Cambridge, UK) was utilized for the determination of malondialdehyde (MDA) content according to the manufacturer's protocol.

Determination of protein carbonyl content

A375 cells were plated in 100 mm dishes, cultured overnight and next day were treated with *L*-SK-4 (100 μ M). After trypsinization, pellets were collected, resuspended and sonicated before the Protein Carbonyl Colorimetric Assay Kit

(Cambridge Bioscience Ltd., Cambridge, UK) was utilized for the determination of protein carbonyl content according to the manufacturer's protocol.

Determination of oxidative DNA damage content

A375 cells were plated in 100 mm dishes, cultured overnight and next day were treated with *L*-SK-4 (100 μ M). After trypsinization, pellets were collected and the dsDNA content was extracted using the PureLinK™ Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA) and then converted to ssDNA according to the manufacturer's protocol. The DNA/RNA Oxidative Damage (High Sensitivity) ELISA Kit (Cambridge Bioscience Ltd., Cambridge, UK) was utilized for the determination of 8-oxo-2-deoxy guanosine (8-OHdG) content according to the manufacturer's protocol.

Lipidomic extraction protocol

A375 cells were plated in 100 mm dishes and cultured overnight at 37 °C. Next day, cells were treated with *L*-SK-4 (100 μ M) and then trypsinised and collected by centrifugation at 2000 rpm for 3 mins at 4 °C. Approximately 3×10^6 cells were washed with ice-cold PBS three times prior to extraction. Then, the cell pellet was re-suspended in 300 μ L of the extraction buffer (dichloromethane/methanol (3:1 v/v) chilled to 4 °C) and cell lysis was induced by snap freezing the samples in liquid nitrogen for 1 min and thaw over ice. This was repeated 5 times to ensure complete cell lysis. Then, cell suspensions were sonicated for 15 mins and ultra-centrifuged at 15,000 rpm for 15 mins. The entire supernatant was transferred to 1.5 mL Eppendorf and allowed to evaporate, at RT, overnight under a fume hood. The dried down extracts were reconstituted in 300 μ L of isopropyl alcohol/ACN/water (2:1:1), sonicated for 15 mins and ultra-centrifuged at 15,000 rpm for an additional 15 mins before transferring 100 μ L to 1.5 mL autosampler vial, capped and then subjected to lipidomic characterization.

Lipidomic sample analysis

LC parameters: Chemical analysis was performed on a Thermo Scientific Orbitrap classic mass spectrometer hyphenated to a Dionex 3000 UHPLC with the autosampler tray set to 4 °C. The separation was performed on a Waters C18 CSH analytical column, 2×100 mm with a 1.7 μ m particle size. The column was maintained at 55 °C with a flow rate of 400 μ L/min. A binary buffer system was used for the chromatographic separation. Buffer A was 60/40 (v/v ACN/MillQ water) and Buffer B (90/10 v/v isopropyl

alcohol and ACN) with 10 mM ammonium formate and 0.1% formic acid.

LC profile: Starting condition: 00.00 min 45% (B) → 11.00 min 65% (B) → 20.00 min 99% (B) → 24.00 min 99% (B) → 24.25 min 45% (B) → 28.50 min 45% (B).

Mass spectrometer: The HESI source condition was as follows: Sheath gas flow: 50, Aux Gas flow: 13, Sweep gas flow: 3. Spray voltage was set 3.5 kV, Capillary temperature was set to 275. S-lens RF level was set to 50 and the temperature of the HESI was set to 425 °C.

Mass spectral acquisition parameter: Scan range was set from 300 to 2000 m/z at mass resolution of 140 K with a scan rate of 1.6 scans/s with an automatic gain control of 1×10^6 with a maximum injection time of 100 ms. MS1 profiling in positive polarity mode.

Peak table generations: Compound discoverer V2, the alignment window was set to 0.25 mins with mass tolerance of 5 ppm with (M-H)⁺ adducts only. Quality control and extraction blanks were imbedded into the analysis for stability assessment and background subtractions.

Statistical analysis

Data were expressed as mean values \pm standard deviation (SD) and comparisons were made between control and treated groups. Statistical analyses were performed by one-way ANOVA with Tukey's test for multiple comparisons, by using the SPSS v.22 software, and statistical significance was set at $p < 0.05$, $p < 0.01$ and $p < 0.001$. For the lipidomic analyses, all multivariate data analyses were performed using the metaboanalyst v3 web-based version (<https://academic.oup.com/bioinformatics/article/34/24/4313/5046255>).

Results

The capacity of HOPOs to induce ROS production

A kinetic characterization of the ability of HOPO-based metal chelators [1,2-HOPO (*rac*-SK-3), 2,3-HOPO (*rac*-SK-5), 3,4-HOPO (*rac*-SK-2, *D/L*-SK-4) and hydroxypyranone (*rac*-SK-1)] to induce ROS generation was evaluated in malignant melanoma cells. Each compound was assessed at a range of concentrations (25–500 μ M) and over 3 time points (24, 48 and 72 h). Our results show that none of the *rac*-SK-1, *rac*-SK-2, *rac*-SK-3 and *rac*-SK-5 compounds were able to induce ROS generation (Figs. 1AI–III and VI). On the other hand, two enantiomerically pure forms of an *N*-substituted-3, 4-HOPO had the capacity to induce a significant elevation of ROS at a concentration of 100 μ M after 24 h of exposure (Figs. 1AIV and V). In particular, when A375 cells were treated with 100 μ M of *L*-SK-4, substantially increased levels of ROS were maintained over the course of 72 h; whereas, in the

case of *D*-SK-4 there was only a slight and dose-dependent elevation of ROS levels throughout the time of exposure (Figs. 1AIV and V). Additionally, the decrease in ROS induced-levels at higher concentrations (500 μ M) suggested that *L*-SK-4 has completely chelated the redox active metals (e.g., Fe(III) and/or Cu(II)) that could be present in different cellular organelles, therefore minimizing the ROS production levels. These observations demonstrated the dual character of *L*-SK-4, which at 100 μ M can act as a pro-oxidant, whereas at higher concentrations (500 μ M) acts as an anti-oxidant. Finally, under similar experimental conditions, we evaluated the capacity of *L*-SK-4 to induce ROS generation against A431 as well as non-tumorigenic HaCaT cells in an attempt to document the selectivity of *L*-SK-4 against A375 cells. Our observations revealed that ROS levels also affected both A431 and HaCaT cells upon treatment with *L*-SK-4 but at a significantly lower magnitude (Fig. 1B and C). Taken together, our data indicate that *L*-SK-4 exerts a higher degree of potency in inducing elevated ROS generation in A375 compared to A431 and HaCaT cells.

Effect of oxidative stress in lipids, proteins and DNA

Then, we sought to determine the nature of ROS generation by means of assessing the content of lipid, protein and DNA oxidation levels. To this end, we firstly examined the levels of malondialdehyde content (MDA; a marker of lipid peroxidation) which were significantly increased as early as 24 h (Fig. 2A). In addition, the levels of protein carbonyl (a marker of protein oxidation; Fig. 2B) and 8-OHdG (a marker of oxidative DNA damage; Fig. 2C) content showed a similar pattern of increase but with statistical significance noted as early as 48 h and throughout the entire time course respectively.

ROS inhibition by GSH

In subsequent experiments, we utilized glutathione (GSH; a well-known ROS scavenger [19, 20]) in order to examine the role of ROS inhibition under the same experimental conditions. A dose-response curve was obtained, in A375 cells, over a range of GSH concentrations (1.5–6.0 mM) at different time points (24–72 h) for determining the optimum experimental conditions of its usage (Fig. 3A). Our data indicated that a GSH concentration of 1.5 mM was well tolerated by the cells as at higher concentrations (3 and 6 mM) a cytotoxic effect was observed (Fig. 3A). Co-treatment of 1.5 mM GSH with 100 μ M of *L*-SK-4 almost abolished the cytotoxic effect of the drug (Fig. 3B) due to inhibition of ROS production (Fig. 3B and C). In addition, we examined the degree of potency of *L*-SK-4 treatment in other melanoma cell lines including brain (VMM1; Fig. 3D) and lymph node metastatic melanoma (Hs294T; Fig. 3E) as well as murine non-metastatic melanoma (B16F-10; Fig. 3F) cells. From our




Fig. 1 Induction of ROS generation by various hydroxypyridinone compounds in melanoma (A375), non-melanoma epidermoid carcinoma (A431) and non-tumorigenic keratinocyte (HaCaT) cells. **(A)** A375 cells were exposed to a range of concentrations (0–500 μM) of **(I)** *rac*-SK-1, **(II)** *rac*-SK-2, **(III)** *rac*-SK-3, **(IV)** *L*-SK-4, **(V)** *D*-SK-4 and **(VI)** *rac*-SK-5 for 24, 48 and 72 h; **(B)** HaCaT and **(C)** A431 cells were exposed to

a range of concentrations (0–500 μM) of *L*-SK-4 for 24, 48 and 72 h. Data shown are means \pm SD of 3 replicates from three independent experiments. Asterisk (*), hashtag (#) or rhombus (◊) denote statistical significance when compare to their respective control at $p < 0.05$. **, ## and ◊◊ denote statistical significance at $p < 0.01$ whereas ***, ###, ◊◊◊ at $p < 0.001$

results, it was evident that treatment with *L*-SK-4 induced a similar trend in increasing ROS levels, during the first 24 h, which was sustained at each time point thereafter. Finally, co-

treatment with GSH and *L*-SK-4 also showed a significant reduction in ROS levels in a manner, similar to that observed in A375 cells (Figs. 3D–F).




Fig. 2 The effect of *L*-SK-4-induced ROS generation on lipids, proteins and DNA in melanoma cells. **(A)** Malondialdehyde (MDA), **(B)** protein carbonyl and **(C)** oxidative DNA damage (8-OHdG) contents upon treatment of A375 cells with 100 μ M of *L*-SK-4 for 24, 48 and 72 h. Data

shown are means of \pm SD of 3 replicates from three independent experiments. Asterisk (*), denotes statistical significance when compare to their respective control at $p < 0.05$. ** denotes statistical significance at $p < 0.01$ whereas *** at $p < 0.001$

GSH prevents *L*-SK-4-induced apoptosis by ROS

Moreover, we determined the levels of apoptotic and necrotic cell populations in A375, VMM1, Hs294T and B16F-10 cell lines after exposure to *L*-SK-4, in the presence or absence of GSH, by utilizing a flow cytometry-based approach. Overall, our data showed a reduction in the levels of viable cells together with increased rates of apoptosis while levels of necrotic cells remained relatively low (Figs. 4AI-III). Additionally, it appeared that treatment with *L*-SK-4 was cytotoxic in the other melanoma cell lines as well including those of VMM1

(Online Resource 1; Fig. S1), Hs294T (Online Resource 2; Fig. S2) and B16F-10 (Online Resource 3; Fig. S3); although they were more resistant compared to A375 cells. Furthermore, necrotic induction rather than apoptotic was recorded in VMM1 (Online Resource 1; Fig. S1), Hs294T (Online Resource 2; Fig. S2) and B16F-10 (Online Resource 3; Fig. S3) cells. However, co-treatment with GSH had a beneficial effect as it reduced the levels of both apoptotic and necrotic cell populations. Finally, we aimed to identify key apoptotic proteins capable of modulating the intrinsic and extrinsic








Fig. 3 The effect of ROS quenching, by GSH, in melanoma cells. **(A)** A375 cells were exposed to a range of GSH concentrations (1.5–3.0 mM) for 24, 48 and 72 h; **(B)** A375 cells were treated with either 100 μM of L-SK-4 or pre-treated with 1.5 mM of GSH, for 2 h, and then co-treated with 1.5 mM of GSH and 100 μM of L-SK-4 for 24, 48 and 72 h; **(C)** GSH scavenges L-SK-4-induced ROS generation in melanoma cell lines; A375 cells were treated with either 100 μM of L-SK-4 or pre-treated with 1.5 mM GSH, for 2 h, and then co-treated with 1.5 mM of GSH and

100 μM of L-SK-4 for 24, 48 and 72 h; ROS levels were analyzed by flow cytometry and quantitated as ROS fold induction. Same experimental conditions were followed for **(D)** VMM1; **(E)** Hs294T and **(F)** B16F-10 melanoma cells. Data shown are means ± SD of 3–5 replicates from three independent experiments. Asterisk (*), hashtag (#) or rhombus (◊) denote statistical significance when compare to their respective control at $p < 0.05$. **, ## and ◊◊ denote statistical significance at $p < 0.01$ whereas ***, ###, ◊◊◊ at $p < 0.001$

apoptotic cascades in response to L-SK-4 treatment (Fig. 4B). To this end, we evaluated the expression levels of i) cleaved and full length Caspase-8 (indicative of extrinsic apoptosis), ii) cleaved and full length Caspase-9 (indicative of intrinsic apoptosis), iii) apoptotic protease-activating factor-1 (Apaf-1; indicative of intrinsic apoptosis) and iv) BID (linker of extrinsic and intrinsic apoptotic cascades). Overall, our results indicated the activation of Caspase-8, BID, Caspase-9 and Apaf-1 (Fig. 4B) all of which have been previously reported to

eventually lead to activation of Caspase-3 and consequently the execution of apoptosis [21–24]. In contrast, when cells were co-treated with GSH, the levels of the above-mentioned proteins were maintained at control levels, suggesting that inhibition of ROS generation (and consequently accumulation) is strongly associated with the activation of apoptosis (Fig. 4B). However, at 48 h post co-treatment, the levels of the listed proteins were increased; nonetheless, at a lesser extent compared to the L-SK-4 treated groups.



◀ **Fig. 4** GSH prevents *L*-SK-4-induced apoptosis in melanoma cells. **(A)** A375 cells were either treated with 100 μ M of *L*-SK-4 or pre-treated with 1.5 mM of GSH, for 2 h, and then co-treated with 1.5 mM of GSH and 100 μ M of *L*-SK-4 for 24, 48 and 72 h. A flow cytometry-based approach was utilized for identifying and quantitating percent of **(I)** viable, **(II)** apoptotic and **(III)** necrotic cell populations; **(B)** Expression levels of full length and cleaved Caspases-8 and -9, BID as well as Apaf-1 proteins were recorded by western immunoblotting

Lipidomic profile of the *L*-SK-4 treated cells

In order to investigate further into how ROS generation modulates the apoptotic response, we performed a lipidomic profiling analysis, in A375 cells, after a 24 h treatment with 100 μ M *L*-SK-4. PCA analysis and visualization indicated a planar separation between control, treated and quality control samples. It was revealed that 1800 lipid MS features (detected by MS1, $n = 4$) have been significantly dysregulated between control and treatment groups (Online Resource 4; Fig. S4). Partial least square-discriminate analysis (PLS-DA, 1 latent variable) was then applied to identify the most statistically significant features (VIP $x > 1$), recognizing 486 lipidated features that were retained (Online Resource 5; Fig. S5). Receiver operating curve (ROC) analysis using Monte-Carlo cross validation was then applied to elucidate the top 40 most significant features. From those, it was confirmed (by matching the MS1; m/z and processing the features via the bioinformatic platform; Thermo Scientific Lipid Search v4) that the elevated lipid classes were associated with de novo biosynthesis of sphingolipids with ceramides being the most significant ones (Fig. 5 and Online Resource 6; Fig. S6).

The role of sphingolipids in ROS-induced apoptosis

According to the literature, elevation in ROS generation can stimulate the release of ceramide species which can act as second messengers for activating apoptosis [25]. In order to validate if a ROS-driven elevation of ceramide levels could induce apoptosis, we utilized Myriocin (an inhibitor of serine palmitoyl transferase [26, 27]) as a treatment vehicle to inhibit de novo biosynthesis of sphingolipids (Fig. 6A). Initially, A375 cells were exposed to a range of Myriocin concentrations (0–50 μ M) over various time periods (24–72 h) for determining the optimum experimental conditions of its usage (Fig. 6B). As a result, A375 cells were treated with 100 μ M of *L*-SK-4 in the presence or absence of 50 nM Myriocin. As expected, the viability levels of A375 cells co-treated with *L*-SK-4 and Myriocin were significantly elevated implying that the utilization of Myriocin partly rescued cells from the observed *L*-SK-4-induced cytotoxicity (Fig. 6C).

Next, we sought to evaluate the effect of Myriocin on *L*-SK-4-induced cell death by means of flow cytometry (Fig. 7AI–III). A similar pattern was observed, in A375 cells

co-treated with *L*-SK-4 and Myriocin, by means of increased levels of viable (Fig. 7AI) and decreased levels of apoptotic cells (Fig. 7AII) while those of necrotic remained relatively unaffected (Fig. 7AIII). The capacity of ceramide to activate extrinsic apoptosis (by inducing FasL stimulation) has been well documented in the literature [28, 29]. Therefore, we aimed to examine the underlying mechanism(s) triggering extrinsic apoptosis as a response to ceramide induction. For this reason, we determined the protein expression levels of Fas and Fas-associated death domain (FADD) as well as those of Caspase-8 and BID, in A375 cells. According to our data, treatment with *L*-SK-4 increased expression levels of Fas, FADD, Caspase-8 and BID, an effect which was significantly minimized after co-treatment with Myriocin; thus suggesting a role of ceramide in modulating the activation of extrinsic apoptosis in A375 cells (Fig. 7B).

Finally, we attempted to further investigate into the effect of increased sphingolipid biosynthesis on the activation of intrinsic apoptosis. For this reason, we utilized flow cytometry and western immunoblotting-based approaches in order to examine levels of mitochondrial membrane depolarization ($\Delta\Psi_m$) (by utilizing JC-1 as a marker of mitochondrial dysfunction; [30, 31]) (Fig. 8A) as well as those of Apaf-1, Caspase 9 and pro-apoptotic regulators BAX and BAK respectively (Fig. 8B and C). According to our results, treatment with 100 μ M of *L*-SK-4 induced a dramatic depolarization of mitochondria while co-treatment with Myriocin re-polarized the mitochondrial membrane, to a variable degree, in A375 cells (Fig. 8A). Furthermore, we examined the expression levels of those proteins closely associated with the formation of apoptosome; namely, Apaf-1 and Caspase-9 both of which were shown to be activated under *L*-SK-4 treatment in A375 cells. In contrast, co-treatment with Myriocin caused a significant reduction in the expression of these proteins (Fig. 8B). In addition, we examined the expression levels of pro-apoptotic proteins BAX and BAK as markers of mitochondria degradation [32, 33] (Fig. 8C). Our data indicated their activation under treatment with *L*-SK-4, an effect which was reversed in the presence of Myriocin, suggesting that ceramide can also induce the activation of pro-apoptotic proteins; thereby, leading to the activation of downstream components of the intrinsic apoptotic cascade.

Discussion

Overexpression of anti-oxidant enzymes leads to an enriched anti-oxidant capacity in human malignant melanoma cells thus allowing them to quench excessive generation of ROS [34, 35]. Previous studies comparing the anti-oxidant capacity between human melanoma cells and normal melanocytes have revealed that melanoma cells possess significantly lower concentrations of intracellular GSH, ferritin, ubiquinone and




Fig. 5 L-SK-4-induced sphingolipids biosynthesis in melanoma cells. A lipidomic analysis-based sphingolipid de novo biosynthetic map shows an up-regulation of sphingolipids biosynthesis after treatment with

100 μM of L-SK-4 (red bars) compared to the respective (untreated) controls (green bars)




Fig. 6 The effect of Myriocin on *L*-SK-4-induced cytotoxicity in melanoma cells. **(A)** Schematic presentation of Myriocin preventing ceramide biosynthesis by inhibition of Serine Palmitoyl Transferase; **(B)** A375 cells were treated with a range (0.01–50 μM) of Myriocin concentrations for 24, 48 and 72 h; **(C)** A375 cells were treated with either 100 μM of *L*-SK-4 or pre-treated with 50 nM of Myriocin, for

4 h, and then co-treated with 50 nM of Myriocin and 100 μM of *L*-SK-4 for 24, 48 and 72 h. Data shown are means ± SD of 5 replicates from three independent experiments. Asterisk (*), hashtag (#) or rhombus (◊) denote statistical significance when compare to their respective control at $p < 0.05$. **, ## and ◊◊ denote statistical significance at $p < 0.01$ whereas ***, ###, ◊◊◊ at $p < 0.001$

catalase therefore making them more vulnerable to extracellular peroxides [36–38]. In contrast, elevated levels of superoxide dismutase (SOD) and vitamin E makes them resistant to oxidative stress while overexpression of NADPH oxidase 1 (induced by intracellular ROS) and superoxide anion are involved in malignant transformation and invasiveness of melanoma [39–41]. Consequently, it can be concluded that the anti-oxidant capacity of melanoma cells is pivotal for their growth and proliferation [42]. On the other hand, other studies have suggested that induction of oxidative stress is responsible for making the anti-oxidant enzymes unable to cope with the toxic levels of ROS, thus leading to excessive ROS accumulation, lipid peroxidation, protein carbonylation and oxidative DNA damage all of which can trigger apoptotic cell death and

therefore can be the target of new therapeutic strategies in malignant melanoma [39].

The capacity of metal chelators to exert an anti-cancer activity has been reported in a variety of in vitro cancer models [43–45]. In a previous study published by our group, we have documented the anti-cancer ability of a newly synthesized series of hydroxypyridinone-based analogues of *L*-Mimosine in an in vitro model of malignant melanoma. From these compounds, a methylated *N*-substituted hydroxypyridinone form was shown to be the most cytotoxic by exerting a higher potency against A375 than A431 and HaCaT cells [18]. Herein, we performed a kinetic determination of ROS induction in a series of HOPO-based analogues of *L*-Mimosine in an attempt to characterize the mode of action of this class of








Fig. 7 Myriocin prevents *L*-SK-4-induced extrinsic apoptosis in melanoma cells. **(A)** A375 cells were treated with 100 μ M of *L*-SK-4 or pre-treated with 50 nM of Myriocin, for 4 h, and then co-treated with 50 nM of Myriocin and 100 μ M of *L*-SK-4 for 24, 48 and 72 h. A flow cytometry-based approach was utilized for identifying and quantitating percent of **(I)** viable, **(II)** apoptotic and **(III)** necrotic cell populations; **(B)** Expression levels of full length and cleaved Caspase-8 as well as BID, FADD and FAS proteins were recorded by western immunoblotting

compounds. Our data suggest that both enantiomers (*L*- and *D*-) of the compound have the ability to induce ROS generation with the *L*- one being more potent (4X) compared to untreated control as well as showing a selectivity for A375 rather than HaCaT and A431 cells.

Fig. 8 Myriocin prevents *L*-SK-4-induced intrinsic apoptosis in melanoma cells. **(A)** A375 cells were treated with either 100 μ M *L*-SK-4 or pre-treated with 50 nM of Myriocin, for 4 h, and then co-treated with 50 nM of Myriocin and 100 μ M of *L*-SK-4 for 24, 48 and 72 h. A flow cytometry-based approach was utilized for quantitating mitochondrial membrane depolarization as the ratio of JC-1 aggregates over JC-1 monomers. Expression levels of **(B)** full length and cleaved Caspase-9 as well as Apaf-1 proteins in addition to **(C)** pro-apoptotic proteins BAK and BAX were recorded by western immunoblotting

Co-treatment of GSH and *L*-SK-4 significantly rescued A375, VMM-1, Hs294T and B16F-10 cells from apoptosis, by reducing ROS levels. This can be attributed to the fact that melanoma cells have generally low levels of GSH and thus are not able to overcome the induction of high levels of ROS generation caused by *L*-SK-4 [43]. Moreover, although induction of both necrosis and apoptosis were recorded, the magnitude of such potency was different among different melanoma cell lines in a way where Hs 294 T, VMM-1 and B16F10 ones were more resistant compared to the A375 one. These findings were validated by western immunoblotting revealing the activation of key apoptotic proteins involved in both intrinsic and extrinsic apoptotic cascades. On the other hand, co-treatment



with GSH reversed this trend and consequently rescued cells from apoptotic cell death indicating a key role of ROS in modulating the apoptotic response. Our findings are in agreement with other studies showing that metal chelators can induce ROS-driven apoptosis [43] and co-treatment with GSH can prevent apoptotic activation [46, 47].

In an attempt to look further into the underlying mechanisms of how *L*-SK-4-induced generation of oxidative stress modulates the apoptotic response, we employed a lipidomic approach in A375 cells. A significant up-regulation of sphingolipid levels was observed with emphasis on those of sphinganine, sphingomyeline, ceramide, phosphatidyl choline, phosphatidyl serine and plasmeyl phosphatidyl ethanolamine. These findings are in agreement with other studies indicating that ROS elevation stimulates the biosynthesis and release of ceramide lipids (as well as other sphingolipids) via ceramide releasing enzymes resulting in generation of a ceramide-enriched membrane [48–50]. Moreover, additional experiments with Myriocin (an inhibitor of the first step of ceramide biosynthesis) confirmed the validity of our observations as inhibition of ceramide synthesis led to the rescue of cells by preventing apoptotic activation. Such preventive action has been explored by other studies suggesting that ceramide (as a bioactive lipid molecule) can act as a second messenger capable of activating directly or indirectly the extrinsic and intrinsic apoptotic pathways respectively [51, 52].

To conclude, we have shown that an N-substituted-3,4-HOPO was the most potent metal chelator capable of inducing cytotoxicity in various melanoma cell lines. Its suggested mode of action involves increased ROS production resulting in significantly increased levels of sphingolipids' (ceramide) biosynthesis which, in turn, can act as second messenger(s) capable of mediating the intrinsic as well as extrinsic apoptosis thereby modulating the therapeutic response of this newly synthesized *L*-SK-4 compound.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10637-021-01087-5>.

Acknowledgments HaCaT cells were kindly provided by Dr. Broby (Dermal Toxicology & Effects Group; Centre for Radiation, Chemical and Environmental Hazards; Public Health England, UK).

Authors' contributions Conceptualization, S.K and M.I.P.; methodology, S.K., W.C., T.M., M.M., D.T.T., R.F., A.P and M.I.P.; formal analysis, S.K., W.C., T.M., M.M., D.T.T., R.F., A.P and M.I.P.; investigation, S.K., W.C and M.I.P.; resources, W.C., D.T and M.I.P.; writing-original draft preparation, S.K., W.C., T.M., I.A and M.I.P.; writing-review and editing, S.K., W.C., T.M., M.M., I.A., S.V., D.T.T., R.F., A.P., D.T and M.I.P.; supervision, M.I.P.; funding acquisition, D.T and M.I.P.

Funding This work was supported by start-up funds to MIP including a PhD studentship obtained from DT in support of SK provided by the Multi-Disciplinary Research Theme in "Bio-economy" of Northumbria University.

Declarations

Conflicts of interest The authors declare no conflict of interest.

Availability of data and material All data generated or analysed during this study are included in this published article and its supplementary information files.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Mittler R (2017) ROS are good. *Trends Plant Sci* 22:11–19
- Prasad S, Gupta SC, Kumar A (2017) Reactive oxygen species (ROS) and cancer: role of anti-oxidative nutraceuticals. *Cancer Lett* 387:95–105
- Yang Y, Bazhin AV, Werner J, Karakhanova S (2013) Reactive oxygen species in the immune system. *Int Rev Immunol* 32:249–270
- Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB (2014) Reactive oxygen species in inflammation and tissue injury. *Antioxid Redox Signal* 20:1126–1167
- Ortis F, Naamane N, Flamez D, Ladiere L, Moore F, Cunha DA, Colli ML, Thukjaer T, Thorsen K, Orntoft TF, Eizirik DL (2010) Cytokines interleukin-1 β and tumour necrosis factor- α regulate different transcriptional and alternative splicing networks in primary β -cells. *Diabetes* 29:358–374
- Yang D, Susan G, Bian EZ, Till OG, Petty HR, Elnor VM (2007) Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. *Exp Eye Res* 84:462–472
- Verbon EH, Post JA, Boonstra J (2012) The influence of reactive oxygen species on cell cycle progression in mammalian cells. *Gene* 511:1–6
- Fu XF, Kun YAO, Xing DU, Yan LI, Yang X, Min YU, Mei-zhang LI, Qinghua CU (2016) PGC-1 α regulates the cell cycle through ATP and ROS in CH1 cells. *J Zhejiang Univ Sci B (Biomed & Biotechnol)*: 136–146
- Yang H, Villani RM, Wang H, Simpson MJ, Roberts MS, Tang M, Liang X (2018) The role of cellular reactive oxygen species in cancer chemotherapy. *J Exp Clin Cancer Res* 37:266–276
- Wei H (1992) Activation of oncogenes and/or inactivation of anti-oncogenes by reactive oxygen species. *Med Hypotheses* 39:267–270
- Kim GH, Kim JE, Rhie SJ, Yoon S (2015) The role of oxidative stress in neurodegenerative diseases. *Exp Neurobiol* 24:325–340
- Avani RP, Ramchandraprasad MV, Bajaj P, Rao NS, Agarwal E (2013) Protein carbonyl: an oxidative stress marker in gingival crevicular fluid in healthy, gingivitis and chronic periodontitis subjects. *Contemp Clin Dent* 4:27–31
- Tang JY, Farooqic AA, Ou-Yang F, Hou MF, Huang HW, Wang HR, Li KT, Fayyazi S, Shui CW, Chang HW (2018) Oxidative stress-modulating drugs have preferential anticancer effects-

- involving the regulation of apoptosis, DNA damage, endoplasmic reticulum stress, autophagy, metabolism and migration. *Semin Cancer Biol* 58:109–117
14. Liu J, Wang Z (2015) Increased oxidative stress as a selective anticancer therapy. *Oxidative Med Cell Longev* 2015:1–12
 15. Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song J, Zevenhoven Z, Los-de Vries T, Horlings H, Nuijen B, Beijnen J, Schellens J, Bernards R (2018) An acquired vulnerability of drug-resistant melanoma with therapeutic potential. *Cell* 173:1–13
 16. Kim JL, Lee DC, Na YJ, Kim BR, Jeong YA, Lee S, Kang S, Joung SY, Lee SY, Oh SC, Min BW (2016) Iron chelators induced apoptosis via the ER stress pathway in gastric cancer cells. *Tumor Biol* 37:9709–9719
 17. Finch RA, Liu M, Grill SP, Rose WC, Loomis R, Vasquez KM, Cheng Y, Sartorelli AC (2000) Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. *Biochem Pharmacol* 59:983–991
 18. Kyriakou S, Mitsiogianni M, Mantos T, Cheung W, Todryk S, Veuger S, Pappa A, Tetard D, Panayiotidis M (2020) Anticancer activity of a novel methylated analogue of *L*-Mimosine against an *in vitro* model of human malignant melanoma. *Investig New Drugs* 38:621–633
 19. Aquilano K, Bardelli S, Ciriolo MR (2014) Glutathione: new roles in redox signalling for an old antioxidant. *Front Pharmacol* 5:1–12
 20. Yao JK, Leonard S, Reddy R (2006) Altered glutathione redox state schizophrenia. *Dis Markers* 22:83–93
 21. Kantari C, Walczak H (2011) Caspase-8 and BID: caught in the act between death receptors and mitochondria. *Biochim Biophys Acta* 1813:558–563
 22. Li P, Zhou L, Zhao T, Liu X, Zhang P, Liu Y, Zheng X, Li Q (2017) Caspase-9: structure, mechanism and clinical application. *Oncotarget* 8:23996–24008
 23. Shakeri R, Kheirollahi A, Davoodi J (2017) Apaf-1: regulation and function in cell death. *Biochimie* 135:111–125
 24. Yuan S, Yu X, Asaram JM, Heuser JE, Ludtke SL, Akey CW (2014) The holo-apoptosome: activation of procaspase-9 and interactions with caspase-3. *Structure* 19:1084–1096
 25. Dumitru CA, Zhang Y, Li X, Gulbins E (2007) Ceramide: a novel player in reactive oxygen species-induced signalling? *Antioxid Redox Signal* 9:1535–1540
 26. Caretti A, Torelli R, Perdoni F, Falleni M, Tosi D, Zulueta A, Casas J, Sanguinetti M, Ghidoni R, Borghi E, Signorelli P (2016) Inhibition of ceramide de novo synthesis by Myriocin produces a double effect of reducing pathological inflammation and exerting antifungal activity against *A. fumigatus* airways infection. *BBA-General Subjects* 1860:1089–1097
 27. Meyer SGE, Wendt AE, Scherer M, Liebisch G, Kerkweg U, Schmitz G, Groot H (2012) Myriocin, an inhibitor of serine palmitoyl transferase, impairs the uptake of transferrin and low-density lipoprotein in mammalian cells. *Arch Biochem Biophys* 526:60–68
 28. Hetz CA, Hunn M, Rojas P, Torres V, Leyton L, Quest AFG (2002) Caspase-dependent initiation and necrosis by the Fas receptor in lymphoid cells: onset of necrosis is associated with delayed ceramide increase. *J Cell Sci* 115:4671–4683
 29. Coe GL, Redd PS, Paschall AV, Lu C, Gu L, Cai H, Albers T, Lebedeva I, Liu K (2016) Ceramide mediates FasL-induced caspase 8 activation in colon carcinoma cells to enhance FasL-induced cytotoxicity by tumor-specific cytotoxic T lymphocytes. *Sci Rep* 6:1–15
 30. Dadsena S, Bockelmann S, Mina JGM, Hassan DG, Komeev S, Razzera G, Jahn H, Niekamp P, Muller D, Schneider M, Tafesse FG, Marrink SJ, Melo MN, Holthuis JCM (2019) Ceramide binds VDAC2 to trigger mitochondrial apoptosis. *Nat Commun* 10:1–12
 31. Hearps AC, Burrows J, Connor CE, Woods GM (2002) Mitochondrial cytochrome c release precedes transmembrane depolarization and caspase 3 activation during ceramide-induced apoptosis of Jurkat T cells. *Apoptosis* 7:387–394
 32. Vince JE, DeNardo D, Gao W, Vince AJ, Hall C, McArthur K, Simpson D, Vijayaraj S, Lindqvist LM, Bouillet P, Rizzacasa MA, Man SM, Silke J, Masrtrers SL, Lessene G, Huang DCS, Gray DHD, Kile BT, Shao F, Laylor KE (2018) The mitochondrial apoptotic effectors BAX/BAK activate Caspase-3 and -7 to trigger NLRP3 Inflammasome and Caspase-8 driven IL-1 β activation. *Cell Rep* 25:2339–2353
 33. Chipuk JE, McStay GP, Bharti A, Kuwana T, Clarke CJ, Siskinf LJ, Obeid LM, Green DR (2012) Sphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosis. *Cell* 148:988–1000
 34. Giles GI (2006) The redox regulation of thiol dependent signalling pathways in cancer. *Curr Pharm Des* 12:4427–4443
 35. Sander C, Hamm F, Elsner P, Thiele J (2003) Oxidative stress in malignant melanoma and non-melanoma skin cancer. *Br J Dermatol* 148:913–922
 36. Ricardo M, Grammatico P, Roccella F (1996) Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. *J Invest Dermatol* 107:322–326
 37. Meyskens FL, Chau HV, Tohidian N, Buckmeier J (1997) Luminol-enhanced chemiluminescent response of human melanocytes and melanoma cells to hydrogen peroxide stress. *Pigment Cell Res* 10:184–189
 38. Fragopoulou E, Gavriil L, Argyrou C, Malagaris I, Choleva M, Antonopoulou S, Afentiu G, Nikolaou E (2018) Suppression of DNA/RNA and protein oxidation by dietary supplement which contains plant extracts and vitamins: a randomized, double-blind, placebo-controlled trial. *Lipids Health Dis* 17:1–11
 39. Liu F, Gomez Garcia AM, Meyskens FL Jr (2012) NADPH oxidase 1 overexpression enhances invasion via matrix Metalloproteinase-2 and epithelial-Mesenchymal transition in melanoma cells. *J Invest Dermatol* 132:2033–2041
 40. Shindo Y, Witt E, Packer L (1993) Antioxidant defence mechanisms in murine epidermis and dermis and their responses to ultraviolet light. *J Invest Dermatol* 100:260–265
 41. Okada K, Takahashi Y, Ohnishi K (1994) Time-dependent effect of chronic UV irradiation on superoxide dismutase and catalase activity in hairless mice skin. *J Dermatol Sci* 8:183–186
 42. Kim KK, Lange TS, Singh RK, Bard L (2010) Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells. *BMC Cancer* 10:6–18
 43. Moon J, Jeong J, Park S (2014) Deferoxamine inhibits trail-mediated apoptosis via regulation of autophagy in human colon cancer cells. *Oncol Rep* 33:1171–1176
 44. Pahl PM, Horwitz MA, Horwitz KB, Horwitz LD (2001) Desferrioxochelin induces death by apoptosis in human breast cancer cells but does not kill normal breast cells. *Breast Cancer Res Treat* 69:69–79
 45. Karg E, Tunek A, Brotell H, Rosengren E, Rosman H (1990) Alteration of glutathione level in human melanoma cells: effect of N-acetyl-L-cysteine and its analogues. *Pigment Cell Melanoma Res* 3:11–15
 46. Franco R, Panayiotidis MI, Cidrowski JA (2007) Glutathione depletion is necessary for apoptosis in lymphoid cells independent of reactive oxygen species. *J Biol Chem* 282:30452–30465
 47. Zou X, Feng Z, Li Y, Wang Y, Wertz K, Weber P, Fu Y, Liu J (2012) Stimulation of GSH synthesis to prevent oxidative stress-induced apoptosis by hydroxytyrosol in human retinal pigment epithelial cells: activation of Nrf2 and JNK-p62/SQSTM1 pathways. *J Nutr Biochem* 23:994–1006
 48. Sanvicens N, Cotter TG (2006) Ceramide is the key mediator of oxidative stress-induced apoptosis in retinal photoreceptor cells. *J Neurochem* 98:1432–1444

49. Abadie NA, Gouaze V, Salvayre R, Levade T (2001) Ceramide in apoptosis signalling: relationship with oxidative stress. *Free Radic Biol Med* 31:717–728
50. Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP (2003) Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. *Cell Death Differ* 10:240–248
51. Friedman AH, Kolesnick RN, Fuks Z (1997) Ceramide signalling in apoptosis. *Brit Med Bull* 53:539–553
52. Koldsnic R, Fuks Z (2003) Radiation and ceramide-induced apoptosis. *Oncogene* 22:5897–5906

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.